Nuwellis, Inc. – What You Need to Know

Thinking about investing in Nuwellis? Before you commit your hard-earned money, let’s break down what this company does in plain English. Use this guide to help you decide if it fits your portfolio.

1. What does this company actually do?

Nuwellis is a medical technology company focused on fluid management. Patients with heart failure or kidney issues often suffer from dangerous fluid buildup. Nuwellis makes the Aquadex SmartFlow system. This high-tech filter gently removes excess fluid from a patient’s blood when standard medications, like diuretics, fail. The system provides ultrafiltration therapy, which is designed to be more precise and easier for patients to tolerate than traditional drugs.

2. What is this new offering about?

As of May 2025, Nuwellis plans to raise approximately $4.2 million by selling a bundle of securities. Instead of just selling stock, they are offering a package that includes:

• Common Stock: Direct ownership in the company.
• Warrants: These act like coupons giving you the right to buy more shares later at a set price.

Important Note on Liquidity: While the common stock trades on the NASDAQ (ticker: NUWE), the warrants will not be listed on any exchange. This makes it very difficult, if not impossible, to sell those "coupons" later.

3. Why are they raising money?

The company needs cash for daily operations, research, clinical studies, and marketing. They also plan to use some of the money to bid on the assets of Arch Therapeutics, which recently filed for bankruptcy. The company didn't provide much detail about the specific strategy behind this acquisition, so it is worth keeping an eye on how they plan to integrate those assets if the bid is successful.

4. What are the main risks?

• "Going Concern" Risk: The company admits there is "substantial doubt" about its ability to stay in business over the next 12 months without more funding. A history of losses and negative cash flow means they must constantly raise money to keep the lights on.
• Regulatory & Legal Minefields: Nuwellis operates under strict laws, including the Anti-Kickback Statute and the Stark Law, which govern how they interact with doctors. If they violate these rules, they could face massive fines, exclusion from Medicare and Medicaid, and severe damage to their reputation.
• Healthcare Policy Changes: Their business relies on hospitals wanting to avoid penalties for readmitting heart failure patients. If government reimbursement policies change, hospitals may use the Aquadex system less, which would hurt Nuwellis's revenue.
• Product Safety & Recalls: In December 2024, the company issued a Class 1 recall—the most serious type—for specific blood circuits due to "weight mismatch" alarms. If these alarms fail, they could lead to dangerous dehydration. Future safety issues could result in significant legal liability and loss of market trust.
• Internal Control Issues: They identified "material weaknesses" in their financial reporting. This means their current accounting processes may not be accurate, which could lead to errors or delays in their financial statements.
• Dilution: The company has many outstanding warrants and stock options. If these are used, the company will issue more shares. This reduces your ownership percentage and the value of your individual slice of the pie.

A quick reminder: I am an AI, not a financial advisor. This company is in a fragile financial position. Before you invest, take a moment to look at the official "Prospectus" on the SEC website—it contains the fine print that every investor should read. Never invest money you cannot afford to lose.